VEDC

Veeva EDC accelerates study cycle times with faster builds, easy amendments, and intuitive data capture, along with next-generation monitoring and data review. Veeva EDC is easily configured for complex trials and allows mid-study amendments with zero downtime or migrations. It is modern, agile, and fast – dramatically improving the user experience for clinical research sites, monitors, and data managers.

With Veeva EDC, companies can design studies more quickly thanks to a modern, drag-and-drop interface. Amendments require zero downtime and no migrations; changes take effect immediately with no interruptions of availability. And role-based views allow stakeholders visibility into their ongoing tasks and current study status at all times.



Benefits

Run the study you want. Veeva EDC handles a wide range of trial complexity without requiring the use of custom functions.

Accelerate study cycle times. Build studies more easily with a modern user interface and configurable workflows. Amendments no longer require downtime or migrations, speeding up cycle times.

Deliver better data, faster. Perform automated data checks for obvious discrepancies upon data entry, eliminating transcription errors and associated data queries.

Features

Studio Design Environment

Veeva EDC offers a visual drag-and-drop study designer that comes with reusable templates and standards library. Innovative features such as dynamic visits and forms, a scripting wizard for edit checks, and self-documenting specs allow studies to be built quickly and efficiently.

Modern Technology for a Better User Experience

Built with the latest cloud technologies, Veeva EDC offers a user experience that greatly increases usability, adoption, and performance. Unlike other systems built on 20+ year-old foundations, Veeva EDC leverages a modern core architecture to provide flexibility, availability, and convenience beyond traditional EDC systems.

Amendments Without Downtime

Make design changes to active studies easily and with no migrations and no downtimes, even for sites. When new requirements are added, any completed forms are reverted to an incomplete state and the new fields are flagged for site personnel to populate. Read more about Veeva's approach to casebook amendments without migrations.

Real-time & Risk-based UAT

A system-generated Study Differences Report accurately documents all changes between two studies. Real-time updates to the casebook or rules during live, interactive UATs speed up testing by eliminating the delays and back- and-forth in a traditional process.

Local Lab Data

Manage local lab units and reference ranges for all studies in a single, central, easy-to-maintain master list. Update reference ranges once and the new normal values are immediately available for all studies.

Assessments

Make assessments of clinical data, such as serious adverse events, by collecting assessor decisions and other data. Assessors see a limited set of read-only data from the subject's casebook to help inform their decision. Vault stores a snapshot of the supporting data along with the assessment.

Direct Access to Study Data

Direct access to study data and self-serve reports accelerates decision-making by allowing trends and safety signals to be recognized faster. Sponsors can receive real- time dashboards displaying the complete status of their data, regardless of who licenses the EDC system — the sponsor or their CRO.

Connection to the Veeva Clinical Platform

As part of the broader Veeva Clinical Platform, data flows bi-directionally from Veeva EDC to various other Veeva applications, including Veeva CDB, Veeva RTSM, Veeva Study Startup, and Veeva eTMF.

Veeva Clinical Platform

The Veeva Clinical Platform is the first eClinical platform offering EDC, CDB, eCOA, eTMF, CTMS, Payments, Site Connect, Study Training, and RTSM on one enterprise-class cloud platform. For the first time, medtech companies can connect clinical operations and data management with a unified platform to create a single source of truth and streamline clinical trials from study startup to close.